Access Bio (950130) Stock Outlook 2026: Malaria Test Supply After the COVID Windfall

Is Access Bio still worth owning after COVID?

Access Bio is the kind of stock that taught a lot of investors a lesson about peak earnings. When pandemic demand pushed antigen tests into every pharmacy and government warehouse, the numbers looked like a new business. When that demand ended, the same numbers looked like a collapse. Neither picture was the whole truth.

My read: the stock is worth a look only if you stop measuring it against its own pandemic peak. What remains is a mid-sized diagnostics company with deep roots in malaria testing, a supply chain built for institutional buyers, and a pipeline of molecular and biosensor products that has not yet proven it can carry the P&L. That is a respectable but uneven setup, not a turnaround guarantee.

It also carries a structural wrinkle most KOSDAQ names do not: the listed parent is a US corporation. You are buying a Korean-listed foreign company, and that changes how you should judge governance, disclosure and shareholder rights.

If you take one thing from this piece, make it this: separate the durable part of the business (endemic-disease testing sold through tenders) from the speculative part (new platforms), and price them differently in your head.

For a comparable “what is left after a hit cycle” exercise in a very different industry, see my write-up on Hana Financial Group, where the question is also how much of today’s earnings is repeatable.

---

What does Access Bio sell, and to whom?

Access Bio develops in vitro diagnostics, meaning tests that work on blood, saliva or swab samples outside the body. The company is headquartered in New Jersey and trades in Seoul.

Product area	Typical use	Business character
Rapid test kits	Malaria, COVID-19, other infectious diseases	Low price, high volume, tender-driven
Biosensor devices	Point-of-care readers and consumables	Installed base with recurring consumable sales
Molecular diagnostics	Near-patient PCR-style platforms	Higher price and margin, long approval path

Rapid kits are the backbone. A malaria test costs very little per unit, so the economics depend on volume, certification and on-time delivery. The customers are not consumers. They are ministries of health, international procurement programs and non-governmental organizations.

Biosensors and molecular platforms are the attempt to move up the value chain. A reader placed in a clinic can pull recurring cartridge sales behind it, which is a far steadier model than winning one-off tenders.

---

Why is malaria testing both steady and unpredictable?

Malaria has not gone away in large parts of sub-Saharan Africa and Southeast Asia. Where microscopy labs and trained technicians are scarce, a lateral-flow test that gives a result in minutes is often the only practical screening tool. So the underlying need is structural, not cyclical.

The unpredictability comes from how that need turns into orders:

• Institutional buyers. Purchasing flows through international funders, ministries and aid programs, each with its own budget calendar.
• Certification gates. Quality approvals such as WHO prequalification open the door to big tenders, but earning and keeping them costs time and money. Several suppliers already hold them, so price competition is real.
• Donor budgets. When funding rounds slip or shrink, shipments get pushed out. Two quarters in the same year can look very different.

In plain terms, the disease is permanent and the order book is lumpy. Anyone who extrapolates from one strong quarter is going to be wrong in one direction or the other.

---

How far can earnings normalize after the pandemic?

The pandemic stretched the diagnostics industry into shapes it will not hold. Governments bought antigen kits in bulk, private testing exploded, and suppliers expanded capacity. Once testing demand dropped, they were left with idle lines, surplus inventory and a cost base built for a bigger world.

Two things usually follow. Revenue steps down, sometimes sharply. Then management spends a year or two resizing: writing down stock, trimming staff, closing or mothballing capacity. Reported losses in that period can look worse than the underlying business deserves.

The useful baseline is not the peak. Think of it as the pre-COVID malaria business, plus the cash and manufacturing capability that survived, minus whatever it costs to fund new products. If results are stabilizing near that baseline, the better question is the slope that comes after: do malaria volumes recover, and do new platforms add something real?

I would not assume a quick V-shaped rebound, and I would not assume permanent decline either. The honest stance is patience with evidence. Look for margin stabilization, inventory clean-up and positive operating cash flow before leaning in.

There is also a pattern worth recognizing. Early in a clean-up, losses look deep because of inventory write-downs and restructuring charges. Next, the one-off items roll off and the loss narrows. Only at the end does the core profit show up. Markets tend to react before that final stage, so by the time the improvement is obvious, expectations may already be in the price. What matters is whether the improvement came from the core business or from the absence of one-time costs.

A different example of normalization after a boom is SK Square, where the discount to the underlying assets is the argument. The mechanics differ, but the discipline of choosing the right baseline is the same.

---

Can molecular diagnostics and biosensors carry the next leg?

A pure malaria strip business does not offer much operating leverage. Even if the market grows, prices are low and competitors are many. That is why the company has been pushing toward higher-value formats.

Molecular diagnostics promise better sensitivity and better pricing, since results approach laboratory-grade accuracy outside a lab. But the field already has large players, and winning share means placing instruments, getting clearances in multiple jurisdictions and building a reagent routine. That takes years.

Biosensors are about the installed base. Once readers are in clinics, consumables follow. If the base grows, revenue becomes more predictable and margins improve.

The risk is timing. R&D and regulatory costs hit the income statement now, while the payoff arrives later, if it arrives. When the rapid-test business is soft at the same time, the new initiatives look expensive.

My practical rule: do not pay today for a platform that has not shown instrument placements or recurring consumable sales. Let the evidence arrive first.

---

What does a US-parent company listed on the KOSDAQ mean for you?

This is where Access Bio differs from almost every other Korean small cap. The parent company is incorporated in the United States. That affects:

• Governance. Board structure, shareholder meetings and related-party rules follow a different legal framework from a Korean company.
• Disclosure. Filings and notices reach Korean shareholders in translated form, sometimes with a delay or different emphasis.
• Shareholder returns. Dividend and capital policy may not follow Korean norms.
• Valuation. Markets often apply a discount to foreign-incorporated names on local exchanges.

None of that is a reason to avoid the stock automatically. Being US-based can help with international sales, regulatory relationships and hiring. But you should not evaluate its governance with the same assumptions you would use for a domestic name, and you should plan to read primary documents rather than rely on summaries.

---

What are the biggest risks?

COVID comparison trap. Using peak earnings as a benchmark guarantees disappointment, while assuming that normalization is complete can be just as costly.

Tender and donor volatility. Orders depend on budgets controlled by others. One missed tender can leave a quarter empty.

Currency. Sales are largely in foreign currencies and the shares trade in won. If you hold through a US broker, you carry won/dollar exposure as well as the equity risk.

Governance and disclosure. The foreign-company structure means more homework on related-party transactions, financing choices and the way information reaches minority holders.

Price competition. Rapid tests are not hard to copy. Certification and supply reliability protect margins only so far.

Execution on new platforms. Molecular and biosensor products need approvals, distribution and sustained funding before they matter.

---

How does Access Bio compare with other diagnostics names?

Company	Core focus	What stands out	Difference from Access Bio
Seegene	Multiplex molecular PCR	Reagents and software, large installed base	Far more molecular-heavy
SD Biosensor	Rapid tests and glucose monitoring	Large scale, broader product lines	Bigger and more diversified
Humasis	Domestic rapid tests	Strong in home market	Less exposure to global procurement
Access Bio	Malaria and infectious-disease rapid tests	Tender-driven, US-parent structure	More endemic-disease and institutional exposure

Access Bio is neither a molecular-platform story like Seegene nor a diversified scale player like SD Biosensor. It is closer to a specialist supplier for institutional buyers, with options on newer technologies. Setting expectations accordingly saves a lot of frustration.

For a Korean healthcare name with a very different, more branded revenue stream, Huons is a useful contrast: consumer-facing products, steadier demand, different risk profile.

---

Three practical scenarios for a US-based investor

Scenario 1: Small starter position, scaled on evidence

Because results swing and the structure is unusual, size the position so a bad quarter does not hurt. Start small, then add only if you see inventory clean-up, steady malaria sales or positive operating cash flow. Do not average down on hope alone.

Also keep in mind that thinly followed small caps can gap on small news. Use limit orders, and know that spreads on a foreign exchange during Seoul hours can be wider than you are used to at home.

Scenario 2: Taxes and foreign accounts

A US taxpayer holding a Korean-listed stock generally reports gains as capital gains, and the holding period determines short-term or long-term rates. Dividends from a foreign issuer may have foreign withholding, and some investors can claim a foreign tax credit. Retirement accounts such as a 401(k) rarely allow direct purchases of individual KOSDAQ shares, and an IRA depends on whether your custodian offers access. Some brokers charge extra for foreign trading, so confirm availability and fees first.

If you are new to the tax side of investing, the broad framework in the guide to capital gains taxes on stocks is a good starting point. Always confirm specifics with a qualified tax professional.

Scenario 3: Event-driven checking, not daily watching

Check the stock around quarterly reports, procurement announcements and regulatory news. Between those events, resist the urge to react to price noise. Many investors lose money in thinly followed small caps by trading headlines instead of facts.

---

What to watch each quarter

1. Revenue mix by product and region. Is malaria steady? How much COVID-related revenue is left?
2. Operating cash flow. Profit that never turns into cash cannot fund the new platforms.
3. Inventory and receivables. Rising inventory points to write-down risk; rising receivables can reflect slow payment from institutional buyers.
4. Currency-adjusted growth. Strip out exchange-rate noise to see real momentum.
5. Regulatory and placement news. Approvals and instrument placements are the proof that molecular and biosensor efforts are moving.
6. Governance filings. Related-party deals, financing decisions and board changes deserve a close read.

If you prefer predictable income, this is not the stock for it. A dividend-focused core such as the one described in the SCHD dividend ETF guide can sit beside a small speculative position like this one, but the two do very different jobs in a portfolio.

---

This article is an opinion for informational purposes only and is not a recommendation to buy or sell any security. Investing involves risk, including loss of principal. Tax treatment depends on your personal situation, so consult a qualified professional, and review current filings before making any investment decision.